Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


For basic questions and answers about HIV testing, visit our HIV testing basics page.

View media fact sheet on HIV testing in the United States.


At the end of 2012, an estimated 1.2 million persons aged 13 and older were living with HIV infection in the United States, including 156,300 (12.8%) persons whose infections had not been diagnosed. The estimated incidence of HIV has remained stable overall in recent years, at about 50,000 new HIV infections per year.

HIV testing is entering a new era in this country as lawmakers, health care and insurance executives, and public health officials are making changes in their respective fields to ensure that more people will know their HIV status – an important consideration for maintaining health and reducing the spread of the virus. In September 2006, CDC released Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings. These Recommendations advise routine HIV screening of adults, adolescents, and pregnant women in health care settings in the United States. They also recommend reducing barriers to HIV testing.

In April 2013, the U.S. Preventive Services Task Force (USPSTF)  issued similar recommendations.  According to these recommendations clinicians should routinely screen adolescents and adults ages 15 to 65 years for HIV infection. Younger adolescents and older adults who are at increased risk should also be screened. They also recommend screening all pregnant women for HIV, including those who present in labor whose HIV status is unknown.

A general rule for those with risk factors is to get tested at least annually. Additionally, CDC has recently reported that sexually active gay and bisexual men may benefit from getting an HIV test more often, perhaps every 3-6 months.  

New data from a National Institutes of Health sponsored trial indicates there is a clear personal advantage to achieving an HIV diagnosis and starting therapy in the early course of infection. This new information further highlights the importance of routine HIV testing and the potential impact on better health outcomes. See Starting Antiretroviral Treatment Early Improves Outcomes for HIV-Infected Individuals for more.

Importance of HIV Testing for Prevention and Treatment of HIV Infection

photo of a doctor talking to a manPeople with HIV who know they are infected can get treatment (antiretroviral medications). Effective treatment keeps HIV infected people healthy and living longer. Studies indicate that all people with HIV infection, including those with early infection, benefit from antiretroviral medications.Treatment with antiretroviral medications lowers the level of HIV in the blood (viral load), reduces HIV-related illness, and reduces the spread of HIV to others.

Knowing they have HIV infection allows people with HIV to protect other people with whom they have sex or share drugs and needles from becoming infected. Knowing that one is positive for HIV helps that person to make better decisions about sex and health care. Studies have shown that many people with HIV who know that they are infected avoid behaviors that spread infection to others with whom they have sex or share drugs and needles. HIV-infected persons who do not know that they are infected do not avoid unsafe behaviors. Persons who know they have HIV can get medical care and take antiviral medications that can reduce HIV spread by as much as 96%.

Knowing that one does not have HIV infection can also help that person make better decisions about sex, drug use, and health care. For example, antiretroviral medications can also be used to prevent HIV infection in persons who are HIV-negative. This is called pre-exposure prophylaxis or PrEP.Doctors planning to prescribe PrEP must conduct testing to ensure that patients are HIV-negative before they start PrEP.

HIV Tests For Screening and Diagnosis

There are three types of HIV diagnostic tests: antibody tests, antigen/antibody tests, and nucleic acid (RNA) tests. Antibody tests detect antibodies, proteins that your body makes against HIV, not HIV itself. Antigen tests and RNA tests detect HIV directly.

An initial HIV test will either be an antibody test or antigen/antibody test. It may involve sending blood or oral fluid to a laboratory or obtaining blood or oral fluid for a rapid test. Blood tests can detect HIV infection sooner after exposure than oral fluid tests because the level of antibody in blood is higher than it is in oral fluid. Likewise, antigen/antibody and RNA tests detect infection in blood before antibody tests. Some newer antigen/antibody lab tests can sometimes find HIV as soon as 3 weeks after exposure to the virus. No antigen/antibody or RNA tests are available for oral fluid.

Follow-up testing is performed if the initial test result is positive. HIV tests are generally very accurate, but follow-up testing allows you and your health care provider to be sure the diagnosis is right. If your initial test is a rapid test and it is positive, you will be directed to get follow-up testing. If your initial test is a laboratory test and it is positive, the laboratory will usually conduct follow-up testing on the same blood specimen as the initial test.
Follow-up tests include:

  • antibody differentiation tests, which distinguishes HIV-1 from HIV-2 antibodies;
  • HIV-1 nucleic acid tests, which looks for the virus RNA directly;
  • Western blot and indirect immunofluorescence assay, which detect antibodies.

CDC has issued revised recommendations for laboratory testing for the diagnosis of HIV infection because of evidence that many persons infected with HIV at the time of testing were not detected by some antibody tests or the Western blot.

If you would like to learn more about HIV tests that are FDA-approved for use in the United States, see Laboratory Tests, Home Tests, and HIV Testing in Non-Clinical Settings.


1 CDC. Prevalence of Diagnosed and Undiagnosed HIV Infection — United States, 2008–2012. MMWR 2015; 64:657-662.

2 CDC. Estimated HIV incidence in the United States, 2007–2010. HIV Surveillance Supplemental Report 2012;17(No. 4). Published December 2012.

3 Smith MK, Rutstein SE, Powers KA, Fidler S, Miller WC, Eron JJ Jr, Cohen MS. The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr.2013; 63 Suppl 2:S187-99

4 Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505.

5 Rietmeijer CA , Kane MS, Simons PZ, et al. Increasing the use of bleach and condoms among injecting drug users in Denver: outcomes of a targeted, community-level HIV prevention program. AIDS 1996;10:291–8.

6 Rhodes F, Malotte CK. HIV risk interventions for active drug users. In: S.Oskamp, S.Thompson, eds. Understanding HIV risk behavior: safer sex and drug use. Thousand Oaks, CA: Sage Publications, 1996:297–36.

7 Gibson DR, Lovelle-Drache J, Young M, Hudes ES, Sorensen JL. Effectiveness of brief counseling in reducing HIV risk behavior in injecting drug users: final results of randomized trials of counseling with and without HIV testing. AIDS and Behavior 1999;3:3–12.

8 Doll LS, O'Malley PM, Pershing AL, Darrow WW, Hessol NA, Lifson AR. High-risk sexual behavior and knowledge of HIV antibody status in the San Francisco City Clinic Cohort. Health Psychol 1990;9:253–65.

9 Cleary PD, Van Devanter N, Rogers TF, et al. Behavior changes after notification of HIV infection. Am J Pub Health 1991;81:1586–90.

10 Fox R, Odaka NJ, Brookmeyer R, Polk BF. Effect of HIV antibody disclosure on subsequent sexual activity in homosexual men. AIDS 1987;1:241–6.

11 van Griensven GJP, de Vroome EMM, Tielman RAP, et al. Effect of human immunodeficiency virus (HIV) antibody knowledge on high-risk sexual behavior with steady and nonsteady sexual partners among homosexual men. Am J Epidemiol 1989;129:596–603.

12 Coates TJ, Morin SF, McKusick L. Behavioral consequences of AIDS antibody testing among gay men [Letter]. JAMA 1987;258:1889.

13 Wenger NS, Kusseling FS, Beck K, Shapiro MF. Sexual behavior of individuals infected with the human immunodeficiency virus: the need for intervention. Arch Intern Med 1994;154:1849–54.

14 Desenclos J-C, Papaevangelou G, Ancelle-Park R, for the European Community Study Group on HIV in Injecting Drug Users. Knowledge of HIV serostatus and preventive behaviour among European injecting drug users. AIDS 1993;7:1371–7.

15 Dawson J, Fitzpatrick R, McLean J, Hart G, Boulton M. The HIV test and sexual behavior in a sample of homosexually active men. Soc Sci Med 1991;32:683–8.

16 Otten MW Jr, Zaidi AA, Wroten JE, Witte J, Peterman TA. Changes in sexually transmitted disease rates after HIV testing and posttest counseling, Miami, 1988 to 1989. Am J Pub Health 1993;83:529–33.

17 Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Eng J Med 2000;342:921–9.

18 CDC. Cases of HIV infection and AIDS in the United States, 2004. HIV/AIDS Surveillance Report 2005;16:16-45.

19 Tao G, Irwin KL, Kassler WJ. Missed opportunities to assess STDs in US adults during routine medical checkups. Am J Prev Med 2000;18:109–14.

20 CDC. HIV prevention practices of primary care physicians—United States, 1992. MMWR 1994;42:988–92.

21 Tiara DA, Safran DG, Seto TB, Rogers WH, Tarlov AR. The relationship between patient income and physician discussion of health risk behaviors. JAMA 1997;278:1412–7.

22 Schwartz JS, Lewis CE, Clancy C, Kinosian MS, Radany MH, Koplan JP. Internists' practices in health promotion and disease prevention. Ann Intern Med 1991;114:46–53.

23 Kassler WJ, Dillon GA, Haley C, et at. On-site, rapid HIV testing with same-day results and counseling. AIDS. 1997;11:1045–51.

24 Horton T, Uniyal A, Smith LV, Curreri S, Kerndt P, Branson B. Feasibility of implementing rapid HIV testing in a community-based setting. National HIV Prevention Conference; Atlanta GA; July 2003. Abstract T2-C1503.

25 Luo W, Masciotra S, Delaney KP, Charurat M, Croxton T, Constantine N, et al. Comparison of HIV oral fluid and plasma antibody results during early infection in a longitudinal Nigerian cohort. J Clin Virol, 2013. 58 Suppl 1: e113-8.

26 Masciotra S, Luo W, Youngpairoj AS, Kennedy MS, Wells S, Ambrose K, et al. Performance of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol, 2013.